Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: PROGNOSTIC-SIGNIFICANCE ; CONSTITUTIVE ACTIVATION ; STEM-CELL TRANSPLANTATION ; NORMAL CYTOGENETICS ; POSTREMISSION THERAPY ; ACUTE MYELOID-LEUKEMIA ; INTERNAL TANDEM DUPLICATION ; ADULT PATIENTS ; FLT3-activating mutations ; FLT3 MUTATIONS
    Abstract: The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITD), as well as concurrent gene mutations with regard to postremission therapy in 323 patients with FLT3-ITD positive acute myeloid leukemia (AML). Increasing FLT3-ITD allelic ratio (p=0.004) and IS in the tyrosine kinase domain 1 (TKD1, p=0.06) were associated with low complete remission (CR) rates. After postremission therapy including intensive chemotherapy (CTX, n=121) or autologous hematopoietic stem cell transplantation (HSCT, n=17), an allelic ratio 〉/=0.51 was associated with an unfavorable relapse-free (RFS, p=0.0008) and overall survival (OS, p=0.004); after allogeneic HSCT (n=93), outcome was significantly improved in patients with a high allelic ratio (RFS, p=0.02; OS, p=0.03), whereas no benefit was seen in patients with low allelic ratio (RFS, p=0.38; OS, p=0.64). Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was observed. The clinical trials described herein were previously published or are registered as follows: AML HD93, reference 29; AML HD98A, reference 30; AMLSG 07-04, ClinicalTrials.gov identifier: NCT00151242.
    Type of Publication: Journal article published
    PubMed ID: 25270908
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: MARROW-TRANSPLANTATION ; STEM-CELL TRANSPLANTATION ; HEMATOLOGIC MALIGNANCIES ; ACUTE MYELOID-LEUKEMIA ; MYELODYSPLASTIC SYNDROMES ; UNRELATED DONORS ; COMORBIDITY INDEX ; PATIENTS OLDER ; REDUCED-INTENSITY ; SIBLING DONORS
    Abstract: The prognosis of elderly patients with AML after chemotherapy is poor. Allo-SCT is feasible in these patients, but data on prognostic factors and outcome are limited. We analyzed all 102 AML patients 〉/=55 years, who underwent allo-SCT at our institution from 1997 to 2008. OS and relapse-free survival (RFS) rates at 3 years are 39 and 37%, respectively. Multivariate analysis for OS revealed age 〉/=60 years and active (refractory or untreated before allo-SCT) or advanced (〉CR1) disease as adverse prognostic factors. Patients transplanted in CR1 had a 3-year OS of 67 vs 27% for patients with active/advanced disease. Multivariate analysis for RFS revealed active/advanced disease as the only adverse factor. Patients transplanted in CR1 had a 3-year RFS of 70 vs 22% for patients with active/advanced disease. In all, 17% of patients suffered from acute GVHD 〉/=grade II. The risk for severe acute GVHD was increased after allo-SCT from mismatched donors. Nonrelapse mortality (NRM) was 23% at 1 year. The only risk factor for NRM was active/advanced disease. In conclusion, allo-SCT from related or unrelated donors yields very good results in elderly AML patients transplanted in CR1. Disease status at transplantation is the most important prognostic factor for transplantation success.Bone Marrow Transplantation advance online publication, 14 June 2010; doi:10.1038/bmt.2010.145.
    Type of Publication: Journal article published
    PubMed ID: 20548341
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...